MoonLake Immunotherapeutics’s Current Ratio at a glance
MoonLake Immunotherapeutics reports current ratio of 21.11 for Dec 2024. The prior period recorded 51.59 (Dec 2023). Year over year the metric moved −30.48 (−59.1%). The rolling three-period average stands at 27.56. Data last refreshed Dec 7, 2025, 1:30 AM.
Latest reading
21.11 · Dec 2024
YoY movement
−30.48 (−59.1%)
Rolling average
27.56
Current Current Ratio
21.11
−30.48
−59.1%
Rolling average
27.56
Latest Value
21.11
Dec 2024
YoY Change
−30.48
Absolute
YoY Change %
−59.1%
Rate of change
3-Period Avg
27.56
Smoothed
Narrative signal
MoonLake Immunotherapeutics’s current ratio stands at 21.11 for Dec 2024. Year-over-year, the metric shifted by −30.48, translating into a −59.1% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How current ratio shapes MoonLake Immunotherapeutics's story
As of Dec 2024, MoonLake Immunotherapeutics reports current ratio of 21.11. Monitor liquidity coverage to understand a company’s ability to meet near-term obligations from working capital.
Reading the current ratio
Ratios above 1.0 indicate more current assets than liabilities. Very high ratios may signal idle capital.
Use with other liquidity metrics
Pair current ratio with quick ratio and cash flow to assess how liquid assets convert to cash.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
MoonLake Immunotherapeutics (MLTX) FAQs
Answers tailored to MoonLake Immunotherapeutics’s current ratio profile using the latest Financial Modeling Prep data.
What is MoonLake Immunotherapeutics's current current ratio?
As of Dec 2024, MoonLake Immunotherapeutics reports current ratio of 21.11. This reading reflects the latest filings and price data for MLTX.
How is MoonLake Immunotherapeutics's current ratio trending year over year?
Year-over-year, the figure shifts by −30.48 (−59.1%). Pair this context with revenue growth and free cash flow signals to gauge momentum for MLTX.
Why does current ratio matter for MoonLake Immunotherapeutics?
The current ratio compares current assets to current liabilities to assess short-term liquidity. For MoonLake Immunotherapeutics, operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is MoonLake Immunotherapeutics's current ratio above its recent average?
MoonLake Immunotherapeutics's rolling three-period average sits at 27.56. Comparing the latest reading of 21.11 to that baseline highlights whether momentum is building or fading for MLTX.
How frequently is MoonLake Immunotherapeutics's current ratio refreshed?
Data for MLTX was last refreshed on Dec 7, 2025, 1:30 AM and updates automatically every 24 hours, keeping your valuation inputs current.